Minimal Residual Disease

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib E Weisberg1,5, A K Azab1,5, P W Manley2, A L Kung3, A L Christie3, R Bronson4, I M Ghobrial1 and J D Griffin1 Abstract: Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment.....read more